The Down Under medical landscape is excited with the emergence of retatrutide, a novel dual GIP and GLP-1 receptor agonist showing remarkable results in early trials for addressing obesity. This treatment https://bookmarkstime.com/story22476545/retatrutide-australia-a-potential-hope-for-weight-management